



The Oncology Institute Achieves \$1.8 Million in Medicare Savings in CMS Enhancing Oncology Model Performance Period 3, Marking Significant Period-Over-Period Improvement

April 13, 2026 1:00 PM EDT

Practice earns maximum quality scores on avoidable ED visits and admissions for second consecutive period; per-episode savings exceed \$6,400

CERRITOS, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, achieved \$1.8 million in Medicare savings during Performance Period 3 of the Centers for Medicare & Medicaid Services' Enhancing Oncology Model (EOM) through its California professional corporation, with savings equating to more than \$6,400 per patient episode. This represents a significant increase from Performance Period 2, when TOI generated \$1.1 million in savings, or more than \$3,500 per episode.

For the second consecutive performance period, TOI earned the maximum score on avoidable emergency department visits and hospital admissions. Results were driven by TOI's High-Value Cancer Care program, including proactive care navigation, Health Care Coach-led symptom monitoring, and 24/7 real-time symptom management, helping patients stay on treatment and avoid unnecessary acute care utilization.

EOM is a voluntary total-cost-of-care model created by the CMS Innovation Center to advance high-quality, person-centered, and equitable cancer care for Medicare Fee-for-Service beneficiaries.

"These results demonstrate continued improvement in both savings and quality," said Yale D. Podnos, MD, MPH, FACS, Chief Medical Officer and President of Practice. "Our model provides exceptional patient care at a lower cost while decreasing unnecessary ED and inpatient utilization."

"This performance reflects the strength and scalability of our value-based oncology model," said Dan Virnich, MD, MBA, FACHE, Chief Executive Officer. "We are increasing savings while maintaining high-quality performance, reinforcing that community-based oncology can deliver meaningful value for patients and Medicare."

TOI's achievements in EOM reinforce its proven history of performance in CMS's prior Oncology Care Model, where the organization consistently surpassed quality benchmarks and delivered substantial savings for Medicare.

About The Oncology Institute (www.theoncologyinstitute.com):

Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers evidence-based oncology and hematology care to approximately 1.9 million patients, including clinical trials, transfusions, and integrated care models. With over 180 employed and affiliated clinicians and more than 100 clinic and affiliate locations across five states, TOI is changing oncology for the better.

Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements generally relate to future events or our future financial or operating performance and may include, but are not limited to, statements regarding expectations, plans, strategies, objectives, prospects, and anticipated results of operations. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology.

These forward-looking statements are based on current assumptions, expectations, and beliefs and are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, changes in general economic, financial, and business conditions; industry trends; competition; regulatory developments; technological changes; and other factors that are beyond our control.

We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof.

Media

The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors

ICR Healthcare
TOI@icrhealthcare.com